SynAct Pharma
8,49 SEK +3,16%1 investor følger denne virksomhed
SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases. The company has developed a platform technology that is aimed at severe conditions in chronic inflammatory diseases, and various joint injuries. The subsidiary SynAct Pharma Aps was initially founded in 2012 and the parent company was established in 2016. The head office is located in Lund.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
SYNACT
Daglig lav / høj pris
8,195 / 8,55
SEK
Markedsværdi
350,61 mio. SEK
Aktieomsætning
798,24 t SEK
Volumen
96 t
Seneste videoer
Finanskalender
Delårsrapport
20.08.2024
Delårsrapport
30.10.2024
Årsrapport
18.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Sanos Group NBCD | 9,6 % | 9,6 % |
Thomas Jonassen | 6,2 % | 6,2 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
SynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
Bulletin from the annual general meeting 2024 in SynAct Pharma AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools